{Reference Type}: Journal Article
{Title}: Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients.
{Author}: Kyr M;Mudry P;Polaskova K;Dubska LZ;Demlova R;Kubatova J;Hlavackova E;Pilatova KC;Mazanek P;Vejmelkova K;Dusek V;Tinka P;Balaz M;Merta T;Kuttnerova Z;Turekova T;Pavelka Z;Pokorna P;Palova H;Mlnarikova M;Jezova M;Kellnerova R;Kozakova S;Slaby O;Valik D;Sterba J;
{Journal}: Int J Cancer
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 3
{Factor}: 7.316
{DOI}: 10.1002/ijc.35062
{Abstract}: A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.